126 related articles for article (PubMed ID: 20178722)
1. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease.
Lundberg S; Lundahl J; Gunnarsson I; Jacobson SH
Clin Nephrol; 2010 Mar; 73(3):221-8. PubMed ID: 20178722
[TBL] [Abstract][Full Text] [Related]
2. Effect of atorvastatin on IgA nephropathy in the rat.
Katzir Z; Leibovitch E; Vaknin H; Schreiber L; Berger E; Matas Z; Fux A; Boaz M; Briliant A; Biro A
Clin Nephrol; 2013 Mar; 79(3):214-20. PubMed ID: 23073067
[TBL] [Abstract][Full Text] [Related]
3. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
Clin Nephrol; 2014 Feb; 81(2):75-85. PubMed ID: 24321183
[TBL] [Abstract][Full Text] [Related]
5. Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals.
Thomas MK; Narang D; Lakshmy R; Gupta R; Naik N; Maulik SK
Cardiovasc Drugs Ther; 2006 Feb; 20(1):37-44. PubMed ID: 16534549
[TBL] [Abstract][Full Text] [Related]
6. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
Grip O; Janciauskiene S; Lindgren S
Inflamm Bowel Dis; 2004 May; 10(3):193-200. PubMed ID: 15290911
[TBL] [Abstract][Full Text] [Related]
7. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
9. Effects of atorvastatin on inflammation and oxidative stress.
Sugiyama M; Ohashi M; Takase H; Sato K; Ueda R; Dohi Y
Heart Vessels; 2005 Jul; 20(4):133-6. PubMed ID: 16025360
[TBL] [Abstract][Full Text] [Related]
10. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
11. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
14. Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients.
Cox SN; Serino G; Sallustio F; Blasi A; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2015 Jul; 30(7):1122-232. PubMed ID: 25770168
[TBL] [Abstract][Full Text] [Related]
15. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.
Prowle JR; Calzavacca P; Licari E; Ligabo EV; Echeverri JE; Haase M; Haase-Fielitz A; Bagshaw SM; Devarajan P; Bellomo R
Nephrology (Carlton); 2012 Mar; 17(3):215-24. PubMed ID: 22117606
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Fuhrman B; Koren L; Volkova N; Keidar S; Hayek T; Aviram M
Atherosclerosis; 2002 Sep; 164(1):179-85. PubMed ID: 12119208
[TBL] [Abstract][Full Text] [Related]
17. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN
Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261
[TBL] [Abstract][Full Text] [Related]
19. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
